Cybin Inc. - CYBN STOCK NEWS

Cybin Inc. (AMEX:CYBN) will report its third-quarter financial results for the period ending December 31, 2021, on February 10, 2022. A conference call will take place at 8:30 a.m. (EST) on the same day, featuring CEO Doug Drysdale and the management team, who will discuss the results and answer questions. Cybin is focused on developing safe and effective therapeutics for mental health issues, leveraging partnerships with leading scientists and proprietary drug discovery platforms. Investors can access a webcast of the call.

Cybin announced approval from an Institutional Review Board for a feasibility study using Kernel's neuroimaging technology to assess ketamine's psychedelic effects on brain activity. This study, authorized by the FDA in October 2021, aims to provide quantitative data on brain activity related to psychedelics, enhancing understanding and potential treatment options for mental health disorders. Enrollment is expected to start in early 2022. Cybin will retain exclusive rights to innovations discovered through this study, aligning with its goal to advance psychedelics to therapeutics.

Cybin Inc. (NYSE AMERICAN:CYBN) has announced that its subsidiary, Adelia Therapeutics Inc., has achieved a milestone under a contribution agreement dated December 4, 2020. As a result, 15,611.4 Class B common shares will be issued to Adelia shareholders, fulfilling a payment obligation of approximately $235,528.90 (CAD). The effective issue price is about $15.09 per Class B Share, which can be exchanged for Cybin Shares at a ratio of 10:1. This strategic move indicates Cybin's commitment to advancing its psychedelic pharmaceutical therapies.

Cybin Inc. (NYSE American:CYBN) provided a year-end summary highlighting significant milestones achieved in 2021. The company expanded its workforce from 5 to over 55 employees globally and partnered with nearly 50 organizations, conducting over 90 preclinical studies. Major achievements included FDA approvals for clinical trials, promising data for CYB003 and CYB004, and a successful capital raise of $70M, totaling over $120M since inception. Cybin aims to initiate four first-in-human clinical studies in 2022, focusing on mental health treatments.

Cybin, a biopharmaceutical company focused on developing therapeutics from psychedelics, announces CEO Doug Drysdale's participation in two virtual investor conferences. The first is the 11th Annual LifeSci Partners Annual Corporate Access Event from January 5-7, 2022, where he will discuss psychedelics on January 5 at 10:00 a.m. ET. The second is the H.C. Wainwright Bioconnect Conference from January 10-13, 2022, featuring a fireside chat available on-demand starting January 10 at 7:00 a.m. ET. More details can be accessed through the company's investor relations website.

Cybin has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 17/394,038, which relates to CYB004, an investigational deuterated psychedelic tryptamine compound aimed at treating anxiety disorders. This patent, expiring in 2041, covers various deuterated forms of DMT and 5-MeO-DMT. The CEO emphasized this milestone enhances Cybin's intellectual property portfolio, reinforcing its innovative position in the evolving mental health landscape.

Cybin Inc. (AMEX:CYBN) announced a significant milestone with a confirmed scientific advice meeting scheduled with the UK Medical and Healthcare Products Regulatory Agency (MHRA) for Q1 2022. This meeting is a key step towards advancing its lead investigational candidate, CYB003, into clinical development, targeting major depressive disorder (MDD) and alcohol use disorder (AUD). Encouraging preclinical results indicate CYB003’s advantages over oral psilocybin, including reduced dose variability, faster onset, and improved brain penetration. A clinical trial application is expected to be filed with the MHRA in Q2 2022.

Cybin, a biopharmaceutical company focused on developing therapeutics from psychedelics, has announced that CEO Doug Drysdale will present at the Stifel GMP 2nd Annual Future of Healthcare Conference.

The event will be held virtually on December 8, 2021, at 3:30 p.m. ET. Interested parties can register and view the presentation via webcast. Cybin aims to create innovative solutions for mental health issues by leveraging proprietary drug discovery platforms and collaborations with leading scientists.

Cybin Inc. has received FDA authorization for a Phase 2 clinical trial focusing on psychedelic-assisted psychotherapy with psilocybin for healthcare workers affected by COVID-related distress. Conducted at the University of Washington under Dr. Anthony Back, the trial aims to treat depression, anxiety, and burnout among frontline clinicians. This study builds on the EMBARK model designed to customize therapy for diverse clinical populations. Cybin's leadership emphasizes the potential of psychedelics to enhance mental health amid ongoing pandemic pressures.